Chemoprevention in familial adenomatous polyposis

Research output: Contribution to journalArticlepeer-review


Familial adenomatous polyposis (FAP) predictably leads to adenomas and eventual adenocarcinomas in the lower gastrointestinal tract and less frequently, the upper gastrointestinal tract. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas in the upper and lower gastrointestinal tract, as well as to prevent recurrence of adenomas in the retained rectum of patients after prophylactic surgery with colectomy and ileorectal anastamosis (IRA). The nonsteroidal anti-inflammatory drug (NSAID) sulindac and selective cyclooxygenase-2 (COX-2) inhibitor celecoxib reduce polyposis of the retained rectum after colectomy with IRA. Reports of cardiovascular risks of some NSAIDs and selective COX-2 inhibitors have led to promising studies of lower doses in combination with ursodeoxycholic acid, statin, and difluoromethylornithine. Curcumin and eicosapentaenoic acid show efficacy in small clinical trials of FAP chemoprevention. This article will review the concept of chemoprevention and the current clinical literature in FAP chemoprevention.

Original languageEnglish (US)
Pages (from-to)607-622
Number of pages16
JournalBest Practice and Research: Clinical Gastroenterology
Issue number4-5
StatePublished - Aug 2011


  • Adenomas
  • Celecoxib
  • Chemoprevention
  • Curcumin
  • Eicosapentaenoic acid
  • Familial adenomatous polyposis
  • Sulindac

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Chemoprevention in familial adenomatous polyposis'. Together they form a unique fingerprint.

Cite this